CLINICAL TRIALS PROFILE FOR SAQUINAVIR

All Clinical Trials for SAQUINAVIR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000848 ↗	The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA. Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have shown that cross-resistance occurs among protease inhibitors, although no clinical trials have been conducted to examine antiretroviral activity with sequential use of protease inhibitors or to determine whether saquinavir resistance can be overcome with higher concentrations of the drug.
NCT00000891 ↗	Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the relationship between viral suppression and changes in immune function, as measured by the restoration of delayed-type hypersensitivity (DTH) and lymphoproliferative (LP) responses, observed after 48 weeks of treatment with highly active antiretroviral therapy (HAART) in ACTG 315. To evaluate the durability of the antiviral and immunologic effects of long-term treatment with HAART. Given the extensive immunologic and virologic data available from ACTG 315, follow-up studies of this advanced-disease population are indicated to primarily ascertain the impact of long-term suppression of viral replication on immunologic reconstitution or re-education and the durability of the antiviral effects of HAART.
NCT00000892 ↗	A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16 weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm. While indinavir is currently the most commonly prescribed protease inhibitor, the optimal therapy for a person on an indinavir-containing regimen who experiences a rebound in viral load or never experiences a decrease in viral load below 500 copies per milliliter is unknown. Current clinical practice for such patients typically involves empiric use of a combination of other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir) and at least 1 other antiretroviral agent to which the patient has had little or no prior exposure. This may involve the use of 1 or more reverse transcriptase inhibitors (RTIs) or nonnucleoside reverse transcriptase inhibitors (NNRTIs). This study attempts to formally evaluate some of these options in indinavir-experienced patients.
NCT00000898 ↗	The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to see if staggering doses of nelfinavir, ritonavir, and saquinavir has any effect on the interactions between these drugs.
NCT00000906 ↗	Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to see if it is safe to combine methadone with two HIV protease inhibitors (PIs), ritonavir (RTV) and saquinavir (SQV), in HIV-infected patients not currently taking PIs. This study will measure the interactions between methadone and the PIs. Methadone is used treat addicts and to treat severe pain. In order to find the safest way to use methadone with PIs, it is important to evaluate how they interact.
NCT00000912 ↗	A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment. This study evaluates the safety of these drug combinations, which include an experimental protease inhibitor (PI), amprenavir. Despite the success that many patients have had with PI treatment regimens, there is still a possibility that patients receiving PIs may continue to have high HIV blood levels. Because of this possibility, alternative drug combinations containing PIs are being studied. It appears that amprenavir, when taken with 3 or 4 other anti-HIV drugs, may be effective in patients with prior PI treatment experience.
NCT00000913 ↗	A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	The purpose of this study is to determine the safety and effectiveness of a soft-gel capsule formulation of saquinavir (SQV-SGC), a protease inhibitor, when given in combination with other anti-HIV drugs. SQV-SGC has been tested in adults for the treatment of HIV infection, but more information is still needed about SQV-SGC in children. Recent studies suggest that this soft-gel capsule form may be safer and more effective than other protease inhibitors.

Clinical Trial Conditions for SAQUINAVIR

Condition Name

Condition Name for SAQUINAVIR
Intervention	Trials
HIV Infections	73
HIV Infection	3
Generalized Anxiety Disorder	1
Major Depression	1

Condition MeSH

Condition MeSH for SAQUINAVIR
Intervention	Trials
HIV Infections	77
Infections	14
Acquired Immunodeficiency Syndrome	11
Infection	11

Clinical Trial Locations for SAQUINAVIR

Trials by Country

Trials by Country for SAQUINAVIR
Location	Trials
United States	482
Canada	24
Puerto Rico	19
Thailand	12
Spain	11

Trials by US State

Trials by US State for SAQUINAVIR
Location	Trials
California	42
New York	40
Illinois	27
Florida	26
Massachusetts	23

Clinical Trial Progress for SAQUINAVIR

Clinical Trial Phase

Clinical Trial Phase for SAQUINAVIR
Clinical Trial Phase	Trials
Phase 4	17
Phase 3	11
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for SAQUINAVIR
Clinical Trial Phase	Trials
Completed	79
Terminated	5
Withdrawn	3

Clinical Trial Sponsors for SAQUINAVIR

Sponsor Name

Sponsor Name for SAQUINAVIR
Sponsor	Trials
Hoffmann-La Roche	26
National Institute of Allergy and Infectious Diseases (NIAID)	21
The HIV Netherlands Australia Thailand Research Collaboration	11

Sponsor Type

Sponsor Type for SAQUINAVIR
Sponsor	Trials
Other	54
Industry	51
NIH	31

Last updated: May 2, 2026

SAQUINAVIR: Clinical Trial Update, Market Analysis, and Projection

Saquinavir is a first-generation HIV protease inhibitor originally approved in multiple jurisdictions. Post-approval clinical activity has largely shifted from first-line, on-patent development toward combination-regimen optimization and durability of benefit in real-world settings. Market impact today is driven by historical penetration, remaining guideline positioning in select regimens, and the commercial shelf life of older formulations rather than new, pipeline-defining efficacy trials.

---

What is the current clinical trial landscape for saquinavir?

Clinical development pattern (what has kept showing up)

Saquinavir’s modern trial footprint is typically characterized by:

• Studies focused on combination antiretroviral regimens where saquinavir is one component
• Trials addressing tolerability, pharmacokinetics, and adherence/continuation rather than de novo efficacy endpoints
• Newer protocol structures aligned with evolving standards of care, even when the drug itself is not the central innovation

Trial activity intensity (directional, not pipeline-renewal)

Across major registries, saquinavir activity is not consistent with an ongoing, drug-resetting phase-development program. Instead, activity is dominated by:

• Lower-frequency interventional postings relative to newer protease inhibitors
• Real-world and regimen-stability evaluation work
• Periodic protocol updates that reflect regimen repositioning rather than a new molecular entrant

Practical takeaway for clinical planning

For investors and R&D leaders, saquinavir’s current clinical trial value is mostly evidence maintenance: continued support for use in defined regimen contexts, rather than a platform for new label expansion.

---

Where does saquinavir sit in treatment and evidence-based practice?

Mechanism and regimen dependency

Saquinavir inhibits HIV-1 protease, which requires use in combination therapy. In practice, its role has been constrained by:

• The protease inhibitor class’s evolution toward newer agents with improved resistance and tolerability profiles
• Historical interactions that shaped formulation and boosting strategies

Label-dependent usage reality

The drug’s market and clinical use track to:

• Whether available formulations and dosing strategies are still supported in local formularies
• Whether clinicians still include it in select salvage or regimen-specific contexts
• Whether patient population and payer criteria allow continued access

Evidence base style

Clinical support tends to come from:

• Combination-regimen outcomes (viral suppression, resistance emergence, tolerability)
• Observational and registry-based data in contemporary cohorts
• Subgroup analyses tied to adherence and persistence

---

What is the saquinavir competitive market structure?

Market category

Saquinavir is now best understood as an older HIV protease inhibitor competing within a crowded, innovation-heavy therapeutic class.

Competitive set (protease inhibitor cohort that has absorbed growth)

In HIV therapy, growth has largely concentrated in:

• Newer protease inhibitors and boosted variants with more favorable resistance/tolerability characteristics
• Treatment simplification approaches that reduce regimen complexity

Commercial implications of being “legacy”

Legacy status creates a structural ceiling:

• Lower sponsor incentives to run expensive global phase-3 programs
• Lower payer pull due to substitution by newer agents
• Formulary volatility across geographies as procurement shifts toward modern options

---

How big is the opportunity for saquinavir today?

Demand drivers

Saquinavir demand today is primarily a function of:

• Residual patient cohorts already treated and continuing therapy
• Availability of specific formulations
• Restriction by local payer policies (formulary inclusion, PA criteria, and step therapy)

Demand inhibitors

Key inhibitors include:

• Patient migration to newer protease inhibitors
• Prescriber preference toward simplified or better-tolerated regimens
• Procurement preference for newer branded or generic protease inhibitors with stronger price-performance

Market sizing approach (useful for investment models)

For a legacy drug like saquinavir, market forecasts typically model:

• A declining treated-population curve
• Offset by new starts only where it is still the preferred or acceptable option due to resistance patterns, tolerability, or access

That produces a pattern of:

• Lower long-term unit growth
• Stability only in bounded settings (certain formularies, salvage contexts, or continuity-of-care patients)

---

What market projection should investors use for saquinavir?

Projection framework

A defensible projection for saquinavir should be built on three components:

1. Treated-population base: current cohort remaining on therapy
2. New starts rate: limited by substitution to newer agents and guideline drift
3. Access and pricing: influenced by generic penetration and payer contracting

Directional outlook

• Near term: modest declines or flattening, depending on local access for remaining cohorts
• Mid to long term: continued volume erosion as patients switch to newer regimens and formularies favor alternatives

Value proposition for stakeholders

Where a legacy agent can still make economic sense is when:

• It is included as a lower-cost option in certain generic markets
• It retains clinical utility in narrow regimen contexts
• It benefits from existing distribution, contracting, and manufacturing scale

---

What are the key IP and commercial constraints impacting saquinavir?

Historical approval status

Saquinavir is an established HIV therapy with long market history. That affects projection mechanics:

• Patent-driven exclusivity is largely not the basis of new revenue growth in 2020s markets
• Commercial performance becomes primarily a function of access and pricing rather than label expansion

Formulation and access dependence

Saquinavir’s economics are also shaped by:

• Product availability in specific countries
• Formulation relevance to contemporary dosing and tolerability expectations
• Generic competition intensity

(For IP and regulatory status in specific jurisdictions, the governing reference point is national regulatory history and the drug’s formal registration records.)

---

Clinical trial signals that matter for any “repositioning” case

If a company attempted to re-activate saquinavir commercially, the signals to watch in trial activity would be:

• Evidence that supports regimen inclusion in defined resistance or intolerability subgroups
• Data demonstrating pharmacokinetic optimization compatible with modern background therapy
• Demonstrated adherence or persistence advantage in real-world cohorts

Absent those signals, saquinavir’s role tends to remain maintenance-level rather than growth-level.

---

Key Takeaways

• Saquinavir’s current clinical activity pattern is consistent with legacy drug evidence maintenance rather than a label-resetting development program.
• Market outlook is driven by treated-population persistence, formulary access, and pricing under generic competition, not by a new efficacy-driven wave.
• Projections should model a declining or stabilizing unit trajectory with bounded new starts, reflecting substitution to newer protease inhibitors and modern regimen preferences.
• Any investment case depends on access economics and narrow regimen utility rather than broad expansion potential.

---

FAQs

1. Is saquinavir still undergoing significant new clinical development?
   Clinical activity exists but is not consistent with a major modern phase-development program that would expand labeling or drive broad new uptake.

2. What drives saquinavir demand in current markets?
   Continuation in existing cohorts, local formulary inclusion, and access rules that determine whether clinicians can prescribe saquinavir in defined contexts.

3. How does competition affect saquinavir unit sales?
   Competitive displacement by newer protease inhibitors and newer regimen structures limits new starts and pushes growth toward price competition.

4. What should a realistic revenue projection model use?
   A treated-population base plus constrained new-start rates, adjusted for generic penetration and payer contracting dynamics.

5. What types of trials would change saquinavir’s commercial outlook?
   Trials that document regimen-specific advantages in defined resistance or tolerability subgroups, with data aligned to modern standard-of-care background therapy.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). SAQUINAVIR (saquinavir mesylate) drug approval reports and labeling history. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] European Medicines Agency. (n.d.). Infectious diseases: antiretrovirals (saquinavir-related assessment and product information references). EMA. https://www.ema.europa.eu/
[3] ClinicalTrials.gov. (n.d.). Saquinavir trials database. U.S. National Library of Medicine. https://clinicaltrials.gov/
[4] International Antiviral Society-USA. (n.d.). Guidelines and treatment recommendations for HIV protease inhibitors. IAS-USA. https://www.iasusa.org/